ClinicalTrials.gg
CompletedNCT03767543LixilanOne CANUpdated Apr 25, 2022

Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)

A Phase 3 interventional study of INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010 in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 32 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 186 studies in Diabetes Mellitus, Type 2 by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Sanofi.

Enrollment
105th of 178
265 · median 334
Started
2019
with 7 others
Phase 3
80 of 186
none open now
Registered
169th of 186
by date

Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 105th largest by enrollment of the 178 interventional ones that give a count, is one of 8 that started in 2019, is one of 80 in phase 3, and was the 169th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 186 studies in Diabetes Mellitus, Type 2 by Sanofi is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Diabetes Mellitus, Type 2 by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate that the simple daily titration algorithm is non-inferior to the weekly titration algorithm according to Canadian labeling.

Secondary Objective:

To gain additional information on the efficacy and safety of using a simple patient-titration protocol for administration of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi).

Read the detailed description

The maximum duration of study per patient is approximately 29 weeks including a 2-week screening, a 26-week randomized active-controlled treatment period, and 3-day post-treatment safety follow-up period.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subject ≥ 18 years
  • Patients with type 2 diabetes mellitus (T2DM) based on Diabetes Canada 2018 Clinical Practice Guidelines criteria and diagnosed at least 6 months prior to the screening visit
  • Uncontrolled glycemia with an A1c ≥7.5% and ≤10.5%
  • Patients treated for at least 6 months on any basal insulin (including but not limited to insulin glargine, Toujeo®, Degludec®, etc.) ± oral anti-diabetic drug (OADs)
  • The total basal insulin dose must be ≤ 40 units/day
  • The OADs allowed at inclusion are metformin, insulin secretagogues, dipeptidyl-peptidase-4 inhibitors (DPP4) inhibitors and SGLT2 inhibitors; with no change in OAD dose for at least 2 months prior to randomization
  • (BMI) between 20 kg/m2 and 40 kg/m2 inclusively

Exclusion criteria

Exclusion criteria:

  • History of severe hypoglycemia or hypoglycemia unawareness
  • History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening visit
  • Current or previous (known intolerance to GLP-1s) treatment with glucagon like peptide-1 (GLP-1) receptor agonist
  • Current use of rapid-acting insulin or premix insulins or use of these insulins within 3 months prior to the screening visit
  • Use of systemic (excluding topical and inhaled forms) for a total duration of 1 week or more within 3 months prior to the screening visit
  • Use of weight loss drugs within 3 months prior to the screening visit
  • Patients with conditions/concomitant diseases that will affect safe participation in this study (e.g. active malignant tumor, major systemic diseases, presence of diabetic retinopathy or presence of macular edema likely to require treatment within the study period, etc.)
  • Women of (WOCBP) not protected by an effective method of birth control and/or who are unwilling or unable to be tested for pregnancy
  • Positive serum pregnancy test in WOCBP, pregnancy or lactation
  • Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to): gastroparesis, unstable (i.e. worsening) or uncontrolled (i.e. prolonged nausea and vomiting) gastroesophageal reflux disease requiring medical treatment within 6 months prior to the time of screening visit
  • History of pancreatitis (unless pancreatitis was related to gallstones and treated with cholecystectomy), pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, pancreatectomy, or stomach/gastric surgery
  • Personal or immediate family history of medullary thyroid cancer or genetic conditions that predispose the patient to medullary thyroid cancer (e.g. multiple endocrine neoplasia syndromes)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
265 participants (actual)

Study arms

  • Experimental
    iGlarlixi DAILY

    Titration Group 1: Addition of 1 unit per day until pre-stated fasting self-monitoring plasma glucose (SMBG) level is reached

    Drug: INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010

  • Active comparator
    iGlarlixi WEEKLY

    Titration Group 2: Algorithm of weekly adjustment until pre-stated fasting self-monitoring plasma glucose (SMBG) level is reached

    Drug: INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010

Interventions

  • DrugINSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010

    Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

06

What researchers measure

Primary outcomes

  1. Change in glycated hemoglobin (HbA1c)%

    Absolute mean change in HbA1c from baseline to Week 26; HbA1c is expressed in % (unit)

    Time frame: Baseline to Week 26

Secondary outcomes

  1. Percentage of patients achieving HbA1c ≤7% at Week 26

    Percentage of patients achieving A1c ≤7%

    Time frame: At Week 26

  2. Change in fasting plasma glucose (FPG) from baseline to Week 12

    Change in FPG from baseline to Week 12

    Time frame: Baseline to Week 12

  3. Change in FPG from baseline to Week 26

    Change in FPG from baseline to Week 26

    Time frame: Baseline to Week 26

  4. Change in fasting self-monitoring plasma glucose (SMPG) from baseline to Week 12

    Change in fasting SMPG from baseline to Week 12

    Time frame: Baseline to Week 12

  5. Change in fasting SMPG from baseline to Week 26

    Change in fasting SMPG from baseline to Week 26

    Time frame: Baseline to Week 26

  6. Change in 7-point SMPG profile from baseline to Week 12

    Change in 7-point SMPG profile from baseline to Week 12

    Time frame: Baseline to Week 12

  7. Change in 7-point SMPG profile from baseline to Week 26

    Change in 7-point SMPG profile from baseline to Week 26

    Time frame: Baseline to Week 26

  8. Change in body weight from baseline to Week 26

    Change in body weight (kg)

    Time frame: Baseline to Week 26

  9. Percentage of patients achieving A1c ≤7% with no body weight gain and/or hypoglycemia (severe or documented symptomatic (≤3.9 mmol/L) at Week 26

    Composite endpoint expressed as percentage of patients A1c ≤7% with no body weight gain and/or hypoglycemia (severe or documented symptomatic (≤3.9 mmol/L)

    Time frame: Baseline to Week 26

  10. Insulin glargine dose

    Insulin glargine dose (expressed in units)

    Time frame: At Week 26

  11. Percentage of patients requiring rescue therapy

    Percentage of patients requiring rescue therapy during the 26-week open-label treatment period

    Time frame: Baseline to Week 26

  12. Percentage of patients experiencing at least 1 hypoglycemia episode (≤3.9 mmol/L) over 26 weeks

    Percentage of patients experiencing at least 1 hypoglycemia episode defined as ≤3.9 mmol/L

    Time frame: Baseline to Week 26

  13. Percentage of patients experiencing at least 1 hypoglycemia episode (<3.0 mmol/L) over 26 weeks

    Percentage of patients experiencing at least 1 hypoglycemia episode defined as \<3.0 mmol/L

    Time frame: Baseline to Week 26

  14. Annualized rate of hypoglycemia (≤3.9 mmol/L) over 26 weeks

    Mean number of hypoglycemia episodes (≤3.9 mmol/L) per patient year of exposure over 1 year

    Time frame: Baseline to Week 26

  15. Annualized rate of hypoglycemia (<3.0 mmol/L) over 26 weeks

    Mean number of hypoglycemia episodes (\<3.0 mmol/L) per patient year of exposure over 1 year

    Time frame: Baseline to Week 26

07

Study locations

32 sites
  • Investigational Site Number 1240004
    Barrie, L4N4L3, Canada
  • Investigational Site Number 1240006
    Brampton, L6S0C9, Canada
  • Investigational Site Number 1240002
    Brampton, L6T4V3, Canada
  • Investigational Site Number 1240005
    Burlington, L7R1A4, Canada
  • Investigational Site Number 1240003
    Calgary, T2H2G4, Canada
  • Investigational Site Number 1240024
    Chicoutimi, G7H7K9, Canada
  • Investigational Site Number 1240014
    Concord, L4K4M2, Canada
  • Investigational Site Number 1240017
    Etobicoke, M9R4E1, Canada
  • Investigational Site Number 1240030
    Greenfield Park, J4V2G8, Canada
  • Investigational Site Number 1240031
    Halifax, B3H1V7, Canada
  • Investigational Site Number 1240026
    Hamilton, L8S4K1, Canada
  • Investigational Site Number 1240011
    Laval, H7T 2P5, Canada
  • Investigational Site Number 1240016
    London, N6A 4V2, Canada
  • Investigational Site Number 1240015
    London, N6G 4X8, Canada
  • Investigational Site Number 1240019
    Mirabel, J7J2K8, Canada
  • Investigational Site Number 1240018
    Montreal, H1M1B1, Canada
  • Investigational Site Number 1240023
    Montreal, H4A2C6, Canada
  • Investigational Site Number 1240020
    Montreal, H4A3T2, Canada
  • Investigational Site Number 1240029
    Montreal, H4T1Z9, Canada
  • Investigational Site Number 1240027
    Nepan, K2J0V2, Canada
  • Investigational Site Number 1240025
    Newmarket, Canada
  • Investigational Site Number 1240021
    Oakville, L6M1M1, Canada
  • Investigational Site Number 1240009
    Oshawa, L1H7K4, Canada
  • Investigational Site Number 1240008
    Quebec, G1G3Y8, Canada
  • Investigational Site Number 1240022
    Quebec, G1V4W2, Canada
  • Investigational Site Number 1240028
    Saint-Lambert, J4P2H4, Canada
  • Investigational Site Number 1240013
    St-Marc-des-Carrieres, Canada
  • Investigational Site Number 1240033
    Toronto, M3J0K2, Canada
  • Investigational Site Number 1240001
    Toronto, M4G3E8, Canada
  • Investigational Site Number 1240012
    Vancouver, V5Y3W2, Canada
  • Investigational Site Number 1240007
    Victoriaville, G6P6P6, Canada
  • Investigational Site Number 1240032
    Winnipeg, R2V4W3, Canada
08

References and documents

Publications

  • Hramiak I, Gerstein HC, Leiter LA, Yale JF, Bajaj HS, Stewart J, Toutounji MJ, Harris SB. Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial. Diabetes Obes Metab. 2022 Oct;24(10):1998-2007. doi: 10.1111/dom.14787. Epub 2022 Jun 29. PubMed 35670659 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Oct 2020, 19 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 19 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2018
First posted
Dec 6, 2018
StartActual
Mar 11, 2019
Primary completionActual
Oct 23, 2020
CompletionActual
Oct 23, 2020
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03767543
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 6, 2018
Start date
Mar 11, 2019
Primary completion
Oct 23, 2020
Completion
Oct 23, 2020
Last update
Apr 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion